PET imaging with FDG to guide revascularization in patients with systolic heart failure

The assessment of myocardial viability is important in the management of patients with coronary artery disease and left ventricular systolic dysfunction. There are several different imaging modalities currently available for the identification of viable myocardium: dobutamine stress echocardiography, single photon emission computed tomography, delayed-enhancement cardiac magnetic resonance imaging, and F-18 fluorodeoxyglucose positron emission tomography. The goal of viability imaging is to determine the likelihood of recovery of systolic function after revascularization. Positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET) provides information about perfusion as well as myocardial metabolism, requires meticulous patient preparation, and is currently the gold standard imaging modality for the assessment of myocardial viability. Viability imaging for the purposes of predicting which patients will have improvement in left ventricular systolic function is supported under current guidelines, but the results of the recent STICH-viability substudy have created uncertainty about the incremental benefit. This review article will provide a summary of the currently available imaging modalities with an emphasis on FDG-PET and discuss the clinical relevance of viability imaging in light of the STICH-viability substudy.